Table 1.
Carcinoma cells with cytoplasmic lipid accumulation in CV-PTC and con-PTC
| CV-PTC (n = 35) |
Con-PTC (n = 100) |
|||
|---|---|---|---|---|
| CLIA (+) | CLIA (–) | CLIA (+) | CLIA (–) | |
| Cases | 21 (60.0)* | 14 (40.0) | 5 (5.0)* | 95 (95.0) |
| Age, years | 17–49 (27.1) | 18–39 (27.2) | 40–77 (55.4) | 18–80 (51.8) |
| Male/female | 0/21 | 0/14 | 1/4 | 14/81 |
| TC, mg/dL | 136–293 (189.2) | 135–255 (175.1) | 178–254 (210.2) | 118–325 (191.8) |
| FAP/non-FAP/NE | 8/9/4 | 8/4/2 | 0/0/5 | 0/0/95 |
| Tumour size, mm | 4–71 (24.6) | 5–46 (21.3) | 6–37 (18.4) | 3–45 (14.8) |
| Microscopic cystic change | 14 (66.7) | 6 (42.9) | 4 (80.0)** | 15 (15.8)** |
| Regional nodal metastasis1 | 1 (4.8) | 1 (7.1) | 3 (60.0) | 58 (61.1) |
| Distant metastasis2 | 0 (0) | 1 (7.1) | 0 (0) | 1 (1.1) |
Data are n (%) or range (mean). CV-PTC, cribriform variant of papillary thyroid carcinoma; con-PTC, conventional papillary thyroid carcinoma; CLIA, carcinoma cells with cytoplasmic lipid accumulation; TC, total cholesterol; FAP, familial adenomatous polyposis; NE, non-examined.
1
At operation.
2
During follow-up.
*
p < 0.001
**
p < 0.01